Trade Panel Bolsters FDA's View In Amarin Omega-3 Complaint
This article was originally published in The Pink Sheet
Executive Summary
International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.